EUVIMEDEUVIMED entdecken
Studienprotokoll

Enhanced Recovery after Surgery Protocol for Anaesthesia: Caveats in Oncosurgical Patients

Shagun Bhatia Shah

Journal of Onco-Anaesthesiology and Perioperative Medicine · 2024

DOI: 10.4103/joapm.joapm_28_24 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Journal of Onco-Anaesthesiology and Perioperative Medicine, 2024. Verfasst von Shagun Bhatia Shah. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The enhanced recovery after surgery (ERAS) protocol initiated on colorectal surgery patients, has currently found widespread acceptance. The ERAS® Society has published many guidelines on different types of surgery, including head-and-neck, obstetric, vascular and orthopaedic surgery.[1] Lower middle-income countries have specific guidelines that are tailor-made for resource-constrained settings. The literature review reveals proven ERAS-related benefits, such as reduced length of surgical intensive care unit and hospital stay and an earlier return to intended oncologic treatment.[2] An ERAS protocol for anaesthesia is also available on the website.[3] Unfortunately, these guidelines are silent on at least five important oncoanaesthesia-specific aspects highlighted below. Dexamethasone is known to cause immunosuppression which promotes cancer progression. Additional side effects include sleep disturbances (in doses >5 mg), hyperglycaemia and perineal pain on intravenous injection. The ERAS protocol recommends dexamethasone as part of first-line multidrug therapy (in addition to serotonin antagonists (IV ondansetron 4 mg), dopamine antagonists (IV droperidol 0.625–1.25 mg) at end surgery or a transdermal scopolamine patch applied 2 h before surgery) for post-operative nausea vomiting (PONV) prophylaxis.[3] In this context, in oncosurgical patients, aprepitant (neurokinin-1 receptor antagonist) may be a better alternative for PONV prophylaxis and treatment since it is even more efficacious than ondansetron as per a recent meta-analysis.[4] IV dexamethasone 4 mg single dose may still be employed where aprepitant is not available A ketogenic diet is a high-fat, low-carbohydrate diet (20–50 g/day) that nearly completely excludes carbohydrates, enabling fatty acids to become the required obligatory supply of mitochondrial energy production in the brain and peripheral tissues.[5] Certain tumours (brain, head-and-neck and lung) use glucose as substrate. These patients should be prescribed a normocaloric ketogenic diet as long as these neoplasms exhibit high fluorodeoxyglucose (18F-FDG) captation.[6] The ERAS protocol recommends carbohydrate loading in cancer patients (100 g maltodextrin at night and 50 g in the morning 2 h before surgery).[3] Is this carbohydrate feeding the cancer cells or the patient? Robust prospective studies are required to satisfactorily answer this pertinent question. Meanwhile, carbohydrate loading may be avoided in brain, head-and-neck and lung cancers and continued for gastrointestinal and other tumours Many oncosurgeries are time sensitive. It is apprehended that the tumour may reach the next stage and even metastasise if surgery is delayed. The ERAS protocol recommends waiting for at least 4–6 weeks before surgery to perform prehabilitation.[3] Cessation of smoking and alcohol for at least 4 weeks is recommended. Optimisation of nutritional status and frailty requires time. How long is it safe to wait before oncosurgery without compromising the oncological outcome? In multimodal prehabilitation programmes (exercise, nutritional, psychosocial, functional and cognitive elements), the duration of prehabilitation is ideally decided by the intervention that entails the lengthiest time to generate a clinically relevant effect. Outpatient exercise programmes may produce substantial benefits for up to 36 weeks, but this exceeds any reasonable pre-operative waiting time.[7] 6-min walk test results showed consistent improvements after exercise prehabilitation lasting at least 3 weeks in colorectal cancer patients.[8] We should utilise the period by beginning prehabilitation from Day 1, which is possible by employing a multidisciplinary approach so that our surgical counterparts refer these patients to the PAC clinic on the 1st hospital visit By 2018, ranitidine had established itself as the third most commonly prescribed gastrointestinal medication in the United States (US). In 2019, the US Food and Drug Administration (FDA) found that ranitidine can elevate the risk of developing cancer by a contaminant (N-nitrosodimethylamine), identified as a human carcinogen in several studies. Its concentration progressively increases over time when stored at high temperatures. In April 2020, the FDA requested manufacturers to withdraw ranitidine (both prescription and over-the-counter), while the European Medicines Agency suspended ranitidine medications in the European Union.[9,10] The ERAS anaesthesia guidelines are probably silent on the use of ranitidine since they were formulated in 2016, much before the association between ranitidine and cancer was reported in the literature and have not been updated since. Mc Gwin compared ranitidine monotherapy with proton pump inhibitor and other H2 antagonist use in 141,963 patients and reported a statistically significant increased risk of pharyngeal, oesophageal, gastric, colorectal, hepatic and pancreatic cancers in ranitidine users.[10] It may be prudent to safely switch to alternatives like pantoprazole/famotidine till further research is available Specificity of bispectral index (BIS) is lower when using total intravenous anaesthesia (TIVA). Propofol-based TIVA is associated with increased overall survival compared with volatile induction and maintenance of anaesthesia (VIMA) with sevoflurane and may eventually emerge as a better option in oncosurgical patients.[11] End-tidal minimum alveolar concentration (MAC) ranging from 0.7 to 1.3 or BIS (40–60) is recommended by the ERAS anaesthesia guidelines.[3] BIS is not infallible, and a lag period exists between EEG changes and BIS.[3] Intraoperative interference by electrocautery and a peripheral nerve stimulator (abundantly used during oncosurgery, especially robotic surgery) are common causes of artefacts in BIS readings. Hence, in the author’s opinion, maintaining an end-tidal MAC of 0.7–1.3 should be the first recommended choice for monitoring the depth of anaesthesia in oncological patients under VIMA. At the same time, BIS remains the option for TIVA, despite caveats. Controversy also shrouds the effects of other anaesthetic–analgesics such as opioids and dexmedetomidine on immunosuppression, cancer progression and recurrence. Untreated acute pain may lead to chronic pain and cancer recurrence, but treating pain with opioids could have a similar result in cancer, which is a catch-22 situation. We should formulate oncoanaesthesia-specific ERAS protocols and guidelines to address these grey areas and fill the gaps in knowledge.

Zitieren

APA

Shah, S. B. (2024). Enhanced Recovery after Surgery Protocol for Anaesthesia: Caveats in Oncosurgical Patients. Journal of Onco-Anaesthesiology and Perioperative Medicine. https://doi.org/10.4103/joapm.joapm_28_24

Vancouver

Shah SB. Enhanced Recovery after Surgery Protocol for Anaesthesia: Caveats in Oncosurgical Patients. Journal of Onco-Anaesthesiology and Perioperative Medicine. 2024. doi:10.4103/joapm.joapm_28_24

BibTeX
@article{Shah2024,
  author = {Shah, Shagun Bhatia},
  title = {Enhanced Recovery after Surgery Protocol for Anaesthesia: Caveats in Oncosurgical Patients},
  journal = {Journal of Onco-Anaesthesiology and Perioperative Medicine},
  year = {2024},
  doi = {10.4103/joapm.joapm_28_24}
}
Kostenlos starten →